Zacks Research Has Pessimistic Outlook of CLB Q2 Earnings

Posted by Brian Himes on Jun 18th, 2026

Core Laboratories Inc. (NYSE:CLB – Free Report) – Equities research analysts at Zacks Research decreased their Q2 2027 EPS estimates for Core Laboratories in a research note issued on Wednesday, June 17th. Zacks Research analyst Team now anticipates that the oil and gas company will post earnings of $0.27 per share for the quarter, down from their previous forecast of $0.28. The consensus estimate for Core Laboratories’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Core Laboratories’ Q4 2027 earnings at $0.23 EPS and FY2027 earnings at $0.82 EPS.

Core Laboratories (NYSE:CLB – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The oil and gas company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $121.80 million for the quarter, compared to the consensus estimate of $122.99 million. Core Laboratories had a net margin of 5.94% and a return on equity of 11.52%. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.14 earnings per share. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Core Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Wall Street Zen cut shares of Core Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, May 25th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

View Our Latest Analysis on Core Laboratories

Core Laboratories Trading Down 6.1%

Core Laboratories stock opened at $11.44 on Thursday. The stock has a market cap of $527.52 million, a P/E ratio of 17.60, a PEG ratio of 2.35 and a beta of 0.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.05 and a quick ratio of 1.50. Core Laboratories has a 1 year low of $9.72 and a 1 year high of $20.36. The firm’s 50 day moving average price is $14.64 and its 200-day moving average price is $16.44.

Core Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Monday, May 11th were given a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, May 11th. Core Laboratories’s payout ratio is currently 6.15%.

Institutional Investors Weigh In On Core Laboratories

Several large investors have recently bought and sold shares of the business. CWM LLC increased its position in Core Laboratories by 36.1% in the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock worth $40,000 after purchasing an additional 668 shares during the last quarter. Platinum Investment Management Ltd. increased its position in Core Laboratories by 3.9% in the third quarter. Platinum Investment Management Ltd. now owns 23,758 shares of the oil and gas company’s stock worth $294,000 after purchasing an additional 889 shares during the last quarter. Illinois Municipal Retirement Fund increased its position in Core Laboratories by 4.0% in the third quarter. Illinois Municipal Retirement Fund now owns 23,366 shares of the oil and gas company’s stock worth $289,000 after purchasing an additional 898 shares during the last quarter. Advisors Capital Management LLC increased its position in Core Laboratories by 0.3% in the third quarter. Advisors Capital Management LLC now owns 275,975 shares of the oil and gas company’s stock worth $3,411,000 after purchasing an additional 912 shares during the last quarter. Finally, Fox Run Management L.L.C. increased its position in Core Laboratories by 5.9% in the third quarter. Fox Run Management L.L.C. now owns 18,531 shares of the oil and gas company’s stock worth $229,000 after purchasing an additional 1,038 shares during the last quarter. Institutional investors own 97.81% of the company’s stock.

About Core Laboratories

(Get Free Report)

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.